Ranbaxy Laboratories Ltd and Daiichi Sankyo Company Ltd announced on Tuesday that Ranbaxy will launch Olvance (Olmesartan Medoxomil, antihypertensive) in India.
The drug was originally discovered by Daiichi Sankyo. This follows a licensing agreement between the two companies authorising Ranbaxy to promote and market the drug in India.
Malvinder Mohan Singh, chairman, CEO and managing director, Ranbaxy, said: “This marks the beginning of a productive engagement that will harness the respective strengths of Daiichi Sankyo and Ranbaxy to establish a much stronger platform for Ranbaxy in India.”
Daiichi Sankyo had acquired Ranbaxy last year. Olvance is an anti-hypertensive agent. The clinical trials of Olmesartan have shown it to be significantly more effective at reducing blood pressure, than, several other agents.
“Ranbaxy has a significant presence in the cardiovascular disease segment and is a leader in Statins, the cholesterol reducing agents. Introduction of Olvance will further strengthen Ranbaxy’s presence in the antihypertensive segment,” a company statement said.